News

Ideas That Generate Results

DNA isolated from the maternal serum called the circulation of cell free DNA is being studied in various labs around the world for the development of various non-invasive prenatal diagnostic tests. Pregnant women are known to have elevated levels of ccff DNA in their plasma. Various mechanisms have been proposed to explain this increased ccff DNA concentration and this has also been used to mitigate the risk of miscarriages. So this ccff DNA has contributed to the growth of NIPT market.
 
According to our report “US Non-Invasive Prenatal Testing Market Outlook 2020”, the rise in high risk births has been contributing to the growth of the NIPT market which is anticipated to witness an impressive double digit growth in the next few years.  This trend has been attributed to numerous factors such as recession and associated affordability issues and women being more careers focused than before.
 
Our report provides a detailed insight into the current scenario and future outlook of the US NIPT market. The demographic scenario of United States has been discussed with focus on the current and future number of births, with the demographics segregated by age and state. Although, the market has witnessed stupendous growth and new tests have gained acceptance rapidly, much of it still remains untapped due to various reasons. This has been discussed in the section dedicated to the potential market for 2014 and 2020.
 
The US NIPT sector is characterized by the presence of players like Sequenom, Verinata, Ariosa and Natera. These players have been profiled with their strengths and weaknesses and latest developments in the field of NIPT. The report provides a prudent analysis of the current and future size of the market weighing the possible pessimistic and optimistic scenarios, is a must buy for players planning to enter the prenatal segment.
 
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM755.htm
 
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm